Covid-19 Vaccines Trials: Understanding the First Published Results #6
With massive awareness in the media, we now have some detailed information about the first of the Covid19 vaccine trials
They differ in clinical usefulness
The efficacy measures of 95% are widely mentioned, but let's be clear about what it means and how can we use that information
In this episode, we go beyond the news coverage to find out and calculate how many persons need to be vaccinated to prevent one Covid19 infection both in general and for subgroups
GET THE ABSTRACT SCREENING TOOL
It can be a challenge to screen papers for clinical relevance. As we go beyond the abstract in this podcast, we have created a screening tool you can use when reading an abstract from a clinical research paper.
Using that tool enables you to quickly screen an abstract from a medical journal for clinical relevance selecting only those you want to read. At the same time, you will know why you skipped the rest. Get it at https://www.precision-evidence.com/tool
In this episode, we follow up on the last episode of the Precision Evidence Podcast where we went beyond the press releases about the Covid19 vaccines
Now we have data from the first trials The Pfizer/BioNTech trial and the AstraZeneca Trial
They are different in many ways
How valid and useful is the data?
The meaning and clinical relevance of efficacy at 95%
How about clinical relevance and precision of the evidence
To find out, we calculate how many persons must get a vaccination to prevent one Covid19 infection, both in general and for age and comorbidity subgroups
Number Needed to Treat (NNT), or instead, Number Needed to Vaccinate
Safety of the vaccines
What is an mRNA vaccine
What do we still not know / and does it matter?
Conclusion and what to expect from other vaccine trials
Podden och tillhörande omslagsbild på den här sidan tillhör
Kim Kristiansen & JG Staal. Innehållet i podden är skapat av Kim Kristiansen & JG Staal och inte av,
eller tillsammans med, Poddtoppen.